Development, implementation and evaluation of Educational tools and Decision Aids for immune checkpoint-inhibitors in advanced LUng cancer: a mixed-methods Study (DEDALUS) / Part I: Development

• Conditions: C34.9; Bronchus or lung, unspecified

• Registration Number: DRKS00032683
• Lead Sponsor: niversitätsklinikum Heidelberg Thoraxklinik Heidelberg

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-09-14
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Stage IV lung cancer, before, under or after immunotherapy (immune checkpoint inhibitors)

Exclusion Criteria

inadequate knowledge of German, incapable of giving informed consent

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Exploration of information needs and preferences, disease and treatment understanding, prognostic awareness, knowledge transfer, influence of personal values and emotions, interaction with health professionals.

Secondary Outcome Measures

Name	Time	Method
Experiences of illness (causes, timeline, control, consequences, coherence, and/or emotional representations), the attitude towards involvement, the interactions, expectations, and relationships with health professionals and involved other persons, decision self-efficacy, decision conflicts, trust, sense of autonomy, coping strategies, barriers for implementation of shared decision making.